Healthcare Global Enterprises Ltd
Healthcare Global Enterprises Ltd is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector.[1]
- Market Cap ₹ 6,527 Cr.
- Current Price ₹ 468
- High / Low ₹ 520 / 310
- Stock P/E 148
- Book Value ₹ 87.6
- Dividend Yield 0.00 %
- ROCE 6.93 %
- ROE 3.64 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 42.4% CAGR over last 5 years
- Company's working capital requirements have reduced from 29.7 days to 20.3 days
Cons
- Stock is trading at 5.34 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.02% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE Allcap BSE Healthcare Nifty Total Market Nifty Microcap 250 BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
291 | 349 | 420 | 471 | 545 | 586 | 640 | 688 | 609 | 850 | 1,006 | 1,099 | 1,148 | |
252 | 336 | 364 | 407 | 462 | 498 | 546 | 573 | 535 | 703 | 824 | 903 | 938 | |
Operating Profit | 39 | 13 | 56 | 64 | 83 | 88 | 94 | 116 | 74 | 147 | 181 | 196 | 210 |
OPM % | 14% | 4% | 13% | 14% | 15% | 15% | 15% | 17% | 12% | 17% | 18% | 18% | 18% |
2 | 3 | 0 | -1 | 7 | 19 | 13 | -19 | -129 | 65 | 7 | 1 | 14 | |
Interest | 25 | 28 | 32 | 34 | 16 | 27 | 48 | 83 | 63 | 43 | 41 | 48 | 67 |
Depreciation | 23 | 28 | 33 | 37 | 44 | 44 | 47 | 79 | 87 | 88 | 89 | 94 | 102 |
Profit before tax | -7 | -40 | -8 | -9 | 29 | 37 | 13 | -65 | -205 | 81 | 58 | 55 | 55 |
Tax % | 9% | -1% | -69% | -45% | 34% | 32% | 42% | -19% | -7% | 53% | 30% | 38% | |
-7 | -40 | -2 | -5 | 19 | 25 | 7 | -53 | -192 | 38 | 40 | 34 | 34 | |
EPS in Rs | -1.05 | -5.79 | -0.34 | -0.56 | 2.27 | 2.86 | 0.82 | -6.01 | -15.28 | 2.75 | 2.89 | 2.44 | 2.46 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 11% |
3 Years: | 22% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 12% |
5 Years: | 42% |
3 Years: | 46% |
TTM: | -7% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 34% |
3 Years: | 23% |
1 Year: | 28% |
Return on Equity | |
---|---|
10 Years: | 1% |
5 Years: | 1% |
3 Years: | 3% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 67 | 68 | 70 | 85 | 86 | 87 | 88 | 89 | 125 | 139 | 139 | 139 | 139 |
Reserves | 217 | 192 | 202 | 435 | 459 | 552 | 557 | 526 | 755 | 959 | 1,006 | 1,049 | 1,082 |
263 | 254 | 311 | 194 | 218 | 264 | 422 | 827 | 481 | 349 | 347 | 740 | 932 | |
96 | 99 | 107 | 136 | 159 | 210 | 337 | 328 | 213 | 197 | 237 | 259 | 257 | |
Total Liabilities | 644 | 614 | 690 | 850 | 923 | 1,112 | 1,404 | 1,769 | 1,575 | 1,644 | 1,730 | 2,188 | 2,410 |
363 | 371 | 405 | 431 | 442 | 492 | 547 | 914 | 745 | 774 | 788 | 938 | 1,096 | |
CWIP | 1 | 10 | 28 | 29 | 33 | 79 | 104 | 44 | 28 | 5 | 9 | 36 | 34 |
Investments | 138 | 80 | 84 | 155 | 141 | 219 | 299 | 316 | 366 | 439 | 475 | 506 | 513 |
142 | 152 | 173 | 235 | 306 | 322 | 454 | 495 | 436 | 426 | 458 | 707 | 767 | |
Total Assets | 644 | 614 | 690 | 850 | 923 | 1,112 | 1,404 | 1,769 | 1,575 | 1,644 | 1,730 | 2,188 | 2,410 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
24 | 34 | 51 | 58 | 54 | 66 | 87 | 86 | 71 | 124 | 130 | 195 | |
-180 | -7 | -74 | -86 | -73 | -185 | -208 | -116 | -246 | 49 | -138 | -249 | |
146 | -19 | 22 | 120 | -14 | 91 | 66 | -3 | 236 | -41 | -42 | 105 | |
Net Cash Flow | -10 | 8 | -1 | 92 | -33 | -27 | -55 | -32 | 61 | 132 | -49 | 51 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 73 | 54 | 56 | 54 | 67 | 79 | 83 | 81 | 88 | 69 | 77 | 68 |
Inventory Days | 33 | 33 | 36 | 30 | 36 | 40 | 39 | 31 | 32 | 30 | 33 | 31 |
Days Payable | 181 | 191 | 208 | 266 | 257 | 269 | 253 | 247 | 214 | 167 | 168 | 197 |
Cash Conversion Cycle | -75 | -104 | -116 | -182 | -154 | -150 | -131 | -135 | -94 | -68 | -59 | -98 |
Working Capital Days | 9 | -33 | -39 | -46 | -41 | -23 | -54 | -72 | 105 | 30 | 39 | 20 |
ROCE % | 4% | -2% | 5% | 5% | 6% | 7% | 6% | 4% | 1% | 5% | 7% | 7% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19 Nov - Of Earnings Call Transcript of the Analysts/Investors Call held on November 1,1, 2024 to discuss on the Unaudited Financial Results of the Company for the …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Regarding newspaper publication on request for issue of duplicate share certificate
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11 Nov - Earnings call held to discuss Q2 results.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Nov - Newspaper advertisement of unaudited financial results for the quarter and six months ended September 30, 2024
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9 Nov - HCG announces Q2 FY25 financial results with strong growth.
Annual reports
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Oct 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020Transcript PPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
Jun 2019TranscriptPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018Transcript PPT
-
Feb 2018TranscriptPPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016Transcript PPT
-
Jun 2016Transcript PPT
Service Offering
The Company is a provider of specialty healthcare focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centers licensed by the AERB. It also provides fertility treatment under our “Milann” brand. [1]